WuXi AppTec Added to Pentagon's Chinese Military Companies List, Raising Supply Chain Concerns for US Pharma
核心洞察
The US Department of Defense added WuXi AppTec to its Section 1260H list of "Chinese military companies," triggering provisions under the Biosecure Act.
WuXi AppTec, which generates three-quarters of its revenue from the US, has denied any association with the Chinese government and plans to appeal the designation.
Under the Biosecure Act, US companies with preexisting contracts have a 5-year transition period starting in 2028, but analysts warn supply chain disruptions could begin much earlier.
The US Department of Defense (DOD) has added WuXi AppTec, one of China's largest drug services companies, to its updated Section 1260H list of "Chinese military companies," reigniting concerns about Chinese firms embedded in the US pharmaceutical supply chain. The updated list, published on Monday, expands the roster to 188 entities from 134, with WuXi AppTec among the newly added names in the healthcare sector.
The Pentagon list asserts that WuXi AppTec is indirectly owned by an institution directly under the State Council of China and is also indirectly affiliated with an agency within the Chinese Ministry of Industry and Information Technology, as well as with the People's Liberation Army.
WuXi AppTec has forcefully rejected the designation. In an open letter to customers, the company stated: "We want to be absolutely clear: WuXi AppTec is not a Chinese military company—not based on an objective review of the facts, and not under the statutory designation criteria for the Section 1260H list under U.S. law." The company added, "We will pursue every available avenue to correct this mistake."
Biosecure Act Implications
The inclusion of WuXi AppTec on the DOD's list triggers provisions under the Biosecure Act, which was signed into law by President Donald J. Trump. The legislation, first introduced in Congress in late 2023, originally named five Chinese life-sciences companies — WuXi AppTec, WuXi Biologics, BGI Group (搜索), MGI Tech (搜索), and Complete Genomics (搜索) — that US federal agencies would be barred from contracting with. When the bill was finally signed into law in December, all five company names had been removed.
However, under the updated Biosecure Act, WuXi AppTec's placement on the 1260H list means the firm is now subject to the act's restrictions. A clause of the act allows US companies with preexisting contracts with the Chinese firm a period of 5 years, starting in 2028, to transition away.
Supply Chain Disruption Concerns
WuXi AppTec generates three-quarters of its revenue from the US, according to Charles Weston, a biotech analyst at RBC Capital Markets. The company has deep integration across the drug development pipeline. At the J.P. Morgan Healthcare Conference earlier this year, WuXi AppTec noted that it had supported the development of 8 of the 30 small-molecule drugs approved by the US Food and Drug Administration in 2025.
Christopher Hencken, a consultant to biotechnology companies and drug services firms, highlighted the difficulty of untangling these relationships on LinkedIn: "WuXi AppTec is not only a manufacturer. It is one of the largest discovery and early-development engines in the world. Medicinal chemistry, screening, intermediates, the building blocks, and raw materials that feed routes long before anything is GMP. That work sits at the front of the pipeline, where programs are smallest and least able to absorb a disruption."
The RBC note further cautioned: "Even if WuXi AppTec is unsuccessful in its appeal, potential timelines for restrictions extend to 2033, but customers would need to make supply decisions several years earlier, and this further adds to concerns about having Chinese companies within pharma supply chains."
Market Reaction and Analyst Views
WuXi AppTec's Hong Kong-traded shares tumbled as much as 5.2% on Tuesday before recovering to close at HK$116.80, down 3.7%. On Wednesday, they rose 2.3% to HK$119.50 by 9:45 am.
Despite the political headwinds, some analysts remain measured. Cui Cui, head of healthcare research for Asia at Jefferies, stated: "We view minimal impact given multinational [companies] in pharma still prefer made-in-China for cost efficiency. Meanwhile, Wuxi AppTec earnings visibility remains intact."
Industry players suggested that the political headwinds were unlikely to derail healthcare collaboration, as the drive to improve patient outcomes and reduce costs would ultimately prevail.
Competitive Landscape Shifts
The uncertainty surrounding WuXi AppTec could create opportunities for competitors. RBC's Weston noted that the company's woes could mean more business for European and North American competitors such as Bachem (搜索), PolyPeptide Group, Charles River Laboratories, and Evotec.